Merck Turns Again To Daewoong For Co-promotion In South Korea
This article was originally published in PharmAsia News
SEOUL - Merck & Co. Inc. signed a co-promotion deal with Korea's Daewoong Pharmaceutical Co. Ltd. to sell Merck's Vytorin (ezetimibe/simvastatin) in Korea, adding to the companies' similar agreements for Fosamax (alendronate) and Januvia (sitagliptin), which have been sold in Korea since 2008
You may also be interested in...
After a fairly smooth launch for its combination drug Olostar in South Korea last year, Daewoong is now taking the product into global markets as part of its international expansion strategy.
South Korean drug companies are looking to make inroads into emerging markets through a combination of distribution deals, and Daewoong Pharmaceutical has made its move through a deal with Turkey’s leading drug company.
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex